tiprankstipranks
Advertisement
Advertisement
SanegeneBio Highlights RNAi Pipeline Progress in Rare and Complement-Mediated Diseases
PremiumPrivate CompaniesSanegeneBio Highlights RNAi Pipeline Progress in Rare and Complement-Mediated Diseases
2M ago
SanegeneBio Secures $200 Million Upfront in Global RNAi Licensing Deal With Genentech
Premium
Private Companies
SanegeneBio Secures $200 Million Upfront in Global RNAi Licensing Deal With Genentech
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100